California Department of Public Health
Immunization Updates for Providers

Friday, January 19, 2024
9:00AM – 10:30AM
Questions

During today's webinar, please use the Q&A panel to ask your questions so CDPH subject matter experts can respond directly.

Resource links will be dropped into, “Chat”
Housekeeping

Reminder to Panelists:

Please mute yourself when not speaking.
Please monitor the Q&A panel for questions you may be able to answer.

Reminder to Attendees:

Today’s session is being recorded. For slides, webinar recordings, and other postings, see the CDPH Weekly Immunization Updates for Providers.

To be added to the CDPH email messaging listserv for providers, please email your request to billiedawn.greenblatt@cdph.ca.gov

If you have post-webinar-related questions, please email leslie.amani@cdph.ca.gov
<table>
<thead>
<tr>
<th>No.</th>
<th>Item</th>
<th>Speaker(s)</th>
<th>Time (AM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Welcome and Announcements</td>
<td>Leslie Amani (CDPH)</td>
<td>9:00 – 9:05</td>
</tr>
<tr>
<td>2</td>
<td>COVID-19 Vaccine Administration Data</td>
<td>Celeste Romano (CDPH)</td>
<td>9:05 – 9:10</td>
</tr>
<tr>
<td>3</td>
<td>Clinical Updates</td>
<td>Caterina Liu, MD (CDPH)</td>
<td>9:10 – 9:20</td>
</tr>
<tr>
<td>4</td>
<td>Therapeutics Billing Update</td>
<td>Edward Salaguinto, PharmD, RPh (CDPH)</td>
<td>9:20 – 9:30</td>
</tr>
<tr>
<td>5</td>
<td>Vaccines for Children (VFC)</td>
<td>Claudia Aguiluz (CDPH)</td>
<td>9:30 – 9:40</td>
</tr>
<tr>
<td>6</td>
<td>Vaccine Management</td>
<td>Josh Pocus (My Turn), Claudia Aguiluz (myCAvax), and Hannah Shows (Demo)</td>
<td>9:40 – 9:50</td>
</tr>
<tr>
<td>7</td>
<td>Resources and Q&amp;A</td>
<td>Leslie Amani (CDPH)</td>
<td>9:50 – 10:30</td>
</tr>
</tbody>
</table>

Thank you, providers of California!
Announcements

Leslie Amani, CDPH
About the Training Series:

- **What:** Building Impact: Your HPI Toolkit Training Series (6 sessions).
  Scroll down below and see attached flyer for details on each session.
- **When:** Sessions run January 2024 to June 2024, with each session scheduled for 60 to 90 minutes.
- **Where:** Virtual - Zoom. Register using the links down below.

**INTRO TO BUILDING IMPACT: YOUR HPI TOOLKIT**

**Register for January 23, 2024, 1:00 to 2:00 PM**

Uncover the power of the NEW California Healthy Places Index® 3.0 in our introductory session. Get oriented to our training series and learn how HPI is used to impact community health across the state.

If you have any questions about this training series, please contact Helen Dowling at hdowling@phi.org.
Project ECHO* Webinar

**Topic:** Respiratory Viruses in Older Californians: Epidemiology Update

**When:** Wednesday, January 24, 2024

**Time:** 12PM – 1PM, PT

**Registration Information:** [Project ECHO Home](#)

---

**Program Overview**

The California Department of Public Health has requested that Family Health Centers of San Diego (FHCSD) in collaboration with the UNM ECHO Institute implement a rapid, 3-4 month long biweekly mini-ECHO series focused on the prevention, diagnosis, and management of SARS-CoV-2, Influenza, and Respiratory Syncytial Virus (RSV) and their respective complications specifically addressing the needs of the Skilled Nursing Facility context and programs focused on older adults. FHCSD and UNM ECHO have previously collaborated on a similar ‘COVID-19 Test to Treat’ initiative directed at clinicians throughout California. The current SNF-targeted program is envisioned as a biweekly interactive webinar ECHO-like platform to engage on clinical issues related to COVID in nursing facilities.

**Target Audience**

We will be targeting clinicians and administrators from Skilled Nursing Facilities, PACE programs, and other older adult-facing programs throughout California.

---

*Extension for Community Healthcare Outcomes*
California Primary Care Association Webinar

**Topic:** Immunization Recommendations During Pregnancy

**When:** Thursday, January 25, 2024

**Time:** 12PM – 1PM, PT

**Cost:** This webinar is sponsored by the CDPH Adult Immunization grant.

**Registration Instructions:** [CPCA Webinar Registration Link](#)

Presenters will review recommended immunizations during pregnancy, including newer RSV vaccines, and best practices for implementing and promoting prenatal immunizations. Participants will also learn, from a health center presenter, practical strategies for immunizing pregnant patients.

**Presenters:**

- Tarek Salih, MD, MPH, MA, Public Health Medical Office, Immunization Branch, CDPH
- Arlene Pena, Senior Program Manager, Quality Improvement, Aliados Health
- Elizabeth Shaw, MD, Family Medicine, Medical Director of Quality Assurance & Improvement, Marin Community Clinics
Look Ahead: Training Opportunities for VFA Providers

**Audience:** Identified Vaccines for Adults (VFA) key practice staff

**Two Training Opportunities:**

- Thursday, February 22, 2024, 11AM, PST: [VFA 101 Training for Providers](#)
- Thursday, February 29, 2024, 11AM, PST: [VFA 102 Training for Providers](#)
Vaccines for Adults (VFA) Resources

EZIZ VFA 317 Resources

VFA 317 FAQs

VFA 317 Resources

Popular Links
- 317 (VFA & VFP) Eligibility Screening & Documentation Requirements
- Vaccination guidance during a Pandemic (2020)
- VFA/VFP Vaccine Eligibility Table
- VFA Reliant Internet Portal (Spanish) | American | Cambodian Chinese (Simplified) | Hindi | Indonesian | Japanese | Korean | Latvian | Lithuanian | Russian | Ukrainian | Vietnamese
- VFA FAQs (April 2023)
- 2023 Progress Participation Requirements at a Glance
- VFA Eligibility Based on Insurance Status
- 317 Eligibility Screening Record for Adult Patients
- Take Action to Prevent Vaccine Use

Resources and Job Aids
- Eligibility
- Vaccine Management

Tools to Implement the Adult Immunization Standards
- Assessments
- Assessment or Refer
- Documentation
- Strategies to Increase Adult Immunization Rates

Webinars
- Year-end 2023
- Best Practices for Adult Immunizations 2023
- Immunization Update 2023
- Program Updates and Year 7 Requirements - January 2023
- Improving Adult Immunization through Community Partnerships
- Adult Immunization Update 2022
- Program Requirements Year 5
- New Provider Orientation
- Adult Immunization Update 2021
- Program Requirements Year 4
- Increasing Adult Flu Vaccination During COVID-19
- Program Requirements Year 4

EZIZ VFA 317 Resources

VFA 317 FAQs
# CDPH Provider Webinars and Trainings

## Week of January 22, 2024

<table>
<thead>
<tr>
<th>Live Webinars and Training</th>
<th>View On Demand</th>
<th>Help</th>
<th>Immunization Resources</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Monday 1/22</strong></td>
<td>• CDPH Weekly Provider Archived Webinars and Slides</td>
<td>New Training Series! Building Impact: Your HPI Toolkit Training Series - Session 1 of 6: Introduction 1:00 pm – 2:00 pm</td>
<td><em>CDPH Provider Call Center: 1-833-502-1245, M-F 8am-5pm</em></td>
</tr>
<tr>
<td></td>
<td>• COVID-19 Crucial Conversations Archived Webinars and Slides</td>
<td></td>
<td>My Turn: Help Desk Email: <a href="mailto:myturn.clinic.hd@cdph.ca.gov">myturn.clinic.hd@cdph.ca.gov</a> Onboarding Email: <a href="mailto:myturnonboarding@cdph.ca.gov">myturnonboarding@cdph.ca.gov</a></td>
</tr>
<tr>
<td></td>
<td>• AIM Vaccine Confidence Toolkit Webinar Series</td>
<td></td>
<td>myCAvax: Help Desk Email: <a href="mailto:mycavax.hd@cdph.ca.gov">mycavax.hd@cdph.ca.gov</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>Introduction to My Turn Onboarding (v. 1/4/22)</em></td>
<td>MyAx: Email: <a href="mailto:stdcb@cdph.ca.gov">stdcb@cdph.ca.gov</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Latest Features in My Turn (Requires myCAvax Login)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• myCAvax Release Notes for LHD and CDPH Users (Requires myCAvax Login)</td>
<td><strong>COVID-19 Treatments:</strong> Warmline for LTCF/SNF staff: 1-866-268-4322, M-F 8am-5pm, <strong>Test to Treat Help Form</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><em>COVID-19 Treatments:</em> Warmline for LTCF/SNF staff: 1-866-268-4322, M-F 8am-5pm, <strong>Test to Treat Help Form</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Tuesday 1/23</strong></td>
<td><strong>Help Desk</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>New Training Series!</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Project Echo Respiratory Viruses in Older Californians Webinar: Research and Epidemiology Update 12:00 pm – 1:00 pm</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Wednesday 1/24</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thursday 1/25</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Friday 1/26</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
COVID-19 Vaccine Administration Data

Celeste Romano, CDPH
COVID-19 Vaccine Administration Summary
as of January 16, 2024

95,025,054
Total Doses Administered:

Daily Doses Administered: Statewide

5,030,496
Total Up-to-Date* Recipients:

Percent of Population Who Are Up-to-Date

12.6%
Statewide

*Has received a dose of the Updated 2023-2024 vaccine

Public Dashboard Link
CDC - Updated 2023-2024 Formula mRNA Vaccine
Trends in COVID-19 Vaccine Administration
as of January 16, 2024

Most Recent Eligibility Groups

• Updated 2023-2024 vaccine for 6 months and older

FDA Authorizes Updated 2023-2024 Vaccine
By race and age:

Highest uptake among NHPI, White, and AIAN

Uptake above statewide average in all 65+ race/ethnicity groups

*Vaccination rate estimates for some groups, such as NHPI, may be affected by differences in how demographic data is collected by the Census and at the time of vaccination.
Updated 2023-2024 COVID-19 Vaccine Doses
Providers and Age
as of January 16, 2024

Majority of Pediatric doses are administered by Healthcare providers while Adults receive most of their doses via Pharmacy.
COVID-19 Vaccine Data Summary
as of January 16, 2024

Key Metrics

95.0 million doses administered | +111K doses administered
12.6% Statewide who are Up-to-Date | 5.0 million Up-to-Date recipients
32.0% 65+ population Up-to-Date | 2.1 million 65+ Up-to-date recipients

System Notes

• Public dashboard Up-to-Date status now includes the Updated 2023-2024 guidelines
  • Public dashboard updated monthly – LHJ Dashboard updated daily
• Email cdphvaccinedatateam@cdph.ca.gov for questions and comments
Clinical
Caterina Liu, MD, CDPH
2024 Immunization Schedules Now Available

- 2024 pediatric and adult immunization schedules initially released in November 2023
- CDC recently published 2 articles in MMWR* summarizing updated recommendations.
  - Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger—United States, 2024
  - Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older—United States, 2024
- Updated schedules include multiple new vaccine recommendations made during 2023, including:
  - RSV immunizations for infants, pregnant people, and older adults
  - PCV20 for children
  - Pentavalent meningococcal vaccine
  - Mpox vaccine
  - Updates to COVID-19, influenza, and polio vaccine recommendations

* Morbidity and Mortality Weekly Report
California Weekly Report Influenza (Flu), RSV, and Other Respiratory Viruses Week 1: December 31, 2023 – January 6, 2024

Respiratory Syncytial Virus Surveillance

RSV Detections from Clinical Sentinel Laboratories

The overall percentage of RSV detections in clinical sentinel laboratories during Week 1 was 9.0% compared to 9.2% during Week 52 (Figure 12).

Figure 12. Percentage of RSV Detections at Clinical Sentinel Laboratories, 2018–2024 Season to Date

Influenza Activity Levels*

<table>
<thead>
<tr>
<th>Geographic Area</th>
<th>Activity Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>California Statewide</td>
<td>Moderate</td>
</tr>
<tr>
<td>Northern Region</td>
<td>Moderate</td>
</tr>
<tr>
<td>Bay Area Region</td>
<td>Moderate</td>
</tr>
<tr>
<td>Central Region</td>
<td>Moderate</td>
</tr>
<tr>
<td>Upper Southern Region</td>
<td>Moderate</td>
</tr>
<tr>
<td>Lower Southern Region</td>
<td>Moderate</td>
</tr>
</tbody>
</table>
Limited Opportunities Remain to Prevent Severe RSV - Order, Use, Reorder Remaining Supplies of Nirsevimab ASAP!

VFC Program:
- 50 mg and 100 mg doses of nirsevimab available now!

Private market:
- Check with distributor
Nirsevimab Resources

RSV Immunization Resources

General Information for Providers
- RSV Immunization Information (CDC)
- RSV Immunization FAQs
- Updated Guidance for Healthcare Providers on Increased Supply of Nirsevimab to Protect Young Children from Severe Respiratory Syncytial Virus (RSV) during the 2023-2024 Respiratory Virus Season
- RSV Trends in the United States (CDC)
- VFC Enrollment Checklist for Birthing/Pediatric Hospitals

Infants and Children
- Optimizing RSV Protection for Infants with Limited Supply of Nirsevimab Infographic
- Nirsevimab Standing Orders (DC
- Nirsevimab (Beyfortus) Guide to Prevent Severe RSV in Infants and Toddlers
- Nirsevimab Guidance (CDC)
- Clinical Guidance to Prevent RSV Disease in Infants Webinar (CDC)
- Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
- Template Parent Portal and Robocall Messages for Infant RSV Immunization
- ACIP and AAP Recommendations for the Use of the Monoclonal Antibody Nirsevimab for the Prevention of RSV Disease (8/15/21)
- Nirsevimab Frequently Asked Questions (AAP)
- Beyfortus (Nirsevimab) Product Insert (FDA)
- CDC recommends new vaccine to help protect babies against severe respiratory syncytial virus (RSV) illness after birth (Press Release)

All Infants <8 Months Entering 1st RSV Season
without prenatal vaccination during 32-36 weeks gestational age*

<table>
<thead>
<tr>
<th>Weight &lt;5kg</th>
<th>Weight ≥5kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nirsevimab 50mg OR Nirsevimab 100mg</td>
<td></td>
</tr>
</tbody>
</table>

or as soon as possible during the RSV season

High-Risk Children 8-19 Months Entering 2nd RSV Season

200mg dose before RSV season
(Two 100mg syringes, same day, different sites, regardless of weight)

Nirsevimab** 100mg + Nirsevimab** 100mg

High-risk conditions include:
- Chronic lung disease of prematurity that required medical support (chronic ventilator therapy, duretic therapy, or supplemental oxygen) any time during the 6-month period before the start of the RSV season
- Cystic fibrosis with either:
  1. Manifestations of severe lung disease (previous hospitalization for pulmonary exacerbation in the 1st year of life or abnormalities on chest imaging that persist when stable OR
  2. Weight-for-length <10th percentile
- Severe immunocompromise
- American Indian or Alaskan Native children

* In limited situations, an infant may be recommended to receive RSV immunization after prenatal vaccination.
** If nirsevimab is unavailable and the child is eligible to receive palivizumab, then palivizumab should be administered.
If <2 doses of palivizumab are administered and nirsevimab becomes available, the child should receive 1 dose of nirsevimab.

California Department of Public Health, Immunization Branch EZIZ.org IMM-1488 (1/2/23)
Trivalent Influenza Vaccine

- Current influenza vaccines are **quadrivalent** and contain 2 influenza A and 2 influenza B strains.
- Given low levels of circulation of B/Yamagata influenza virus, experts have recommended that this strain be removed. This would result in a **trivalent** flu vaccine.
- We may see both trivalent and quadrivalent vaccines during the 2024-2025 influenza season.
  - If both trivalent and quadrivalent vaccines are available, both will be recommended.
- Trivalent and quadrivalent flu vaccines have similar safety profiles and are expected to offer similar protection.
- For more information, see here: [B/Yamagata and Flu Vaccines Summary | CDC](https://www.cdc.gov/flu/professionals/uvb/virus-vaccine-guidance.htm); [Trivalent versus Quadrivalent Vaccines | CDC](https://www.cdc.gov/flu/professionals/uvb/virus-vaccine-guidance.htm)
Update on Billing for Pharmacists Prescribing Paxlovid

- Business and Professions Code 4052.04 states a pharmacist may furnish COVID-19 oral therapeutics following a positive test for SARS-CoV-2.

- Claims for reimbursement of the professional dispensing fee and ingredient cost must be submitted to Medi-Cal Rx for processing.

- Department of Healthcare Services (DHCS) will reimburse pharmacists for the prescribing (consultation and assessment of need for treatment) of all Paxlovid products.

- Claims must continue to be billed to DHCS as a medical claim on a CMS-1500 form as a Pharmacist Service.
  - Use CPT codes 99202 (new patient) and 99212 (existing patient);
  - Eligible claims must have an ICD-10-CM diagnosis code, U07.1 (COVID-19).

- DHCS is extending the temporary allowance to allow billing with these CPT codes from the end of the PHE (May 11, 2023) through September 30, 2024.
Vaccines for Children (VFC)
Claudia Aguiluz, CDPH
Continue Ordering Nirsevimab (Beyfortus™)

- Additional allocations of the 100mg and 50mg Beyfortus™ have been received from CDC!
- All VFC providers may order 50mg and 100 mg doses of nirsevimab (Beyfortus™) via supplemental orders.
- Current limits and eligibility are subject to change based on supply.
• RSV vaccine ABRYSVO (NDC: 00069-0344-01) is provided through the VFC Program in a 1-pack, 1-dose vial.
  o The minimum order quantity is 1 dose.

• ABRYSVO™ is recommended for pregnant people during 32 through 36 weeks gestation, using seasonal administration (Sept – January), to prevent RSV lower respiratory tract infection in infants.

• Given the small size of the eligible population and the recommended window for vaccination, the amount of vaccine available within the VFC program is modest. As a result, CDC has allocated doses to each state.
12 Days Remain! Submit your 2024 VFC Recertification!

- VFC Recertification Launched: **December 20, 2023**
- **Due date:** **Wednesday, January 31, 2024**

- Annual 2024 Recertification is completed through MyVFCvaccines
  - Annual Recertification and Training is a **federal requirement** to maintain active status in the VFC Program and receive publicly purchased vaccines.

- All public and private providers must recertify yearly
  - Even if an LHD clinic is only receiving LHD 317 vaccine for outbreak or SGF vaccine
  - Recertification maintains the PIN’s active status
A link to complete and submit the VFC Provider Satisfaction Survey will appear after submitting the Recertification form.

Your input is greatly valued and will guide enhancement to our program, educational resources, staff training, and systems.

If you haven’t had a chance to complete it yet, please complete the survey to finalize your VFC Recertification for 2024.
VFC 2024-2025 Flu Vaccine Pre-Book

• Launch: 1/19 or early next week

• VFC Provider Deadline: February 2, 2024

• CDC Pre-Book due date: February 9, 2024

• Final individual pre-book confirmation emails will be sent to providers after we receive CDC’s approval of our CA pre-book.

• Prebooking is the first of three phases of the 2024-2025 VFC flu vaccine order process and will be providers’ ONLY chance to provide Flu Product brand preference AND the number of doses needed next season.
## Expected 2024-2025 Flu Vaccine Products

- Actual products that will be available for 2024-2025 VFC Flu Ordering will be dependent upon demand, product availability, and doses approved by the CDC.
- Changes for next season:
  - Fluarix will *not* be on the CDC pediatric contract but will be on the CDC adult contract.
  - FluLaval remains on the CDC pediatric contract but will *not* be on the CDC adult contract.

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Product</th>
<th>Presentation</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 months-18 years</td>
<td><strong>Flucelvax®</strong></td>
<td>Inactivated, No Preservative, 0.5mL single-dose syringe, 10 pack*</td>
<td>Seqirus</td>
</tr>
<tr>
<td></td>
<td><strong>FluLaval®</strong></td>
<td>Inactivated, No Preservative, 0.5mL single-dose syringe, 10 pack*</td>
<td>GSK</td>
</tr>
<tr>
<td></td>
<td><strong>Fluzone®</strong></td>
<td>Inactivated, No Preservative, 0.5mL single-dose syringe, 10 pack*</td>
<td>Sanofi</td>
</tr>
<tr>
<td>2-18 years</td>
<td><strong>FluMist®</strong></td>
<td>Live Attenuated, 0.2mL nasal sprayer</td>
<td>AstraZeneca</td>
</tr>
</tbody>
</table>
Completing your VFC Flu Vaccine Pre-Book for the Upcoming 2024-2025 Influenza Season

2024 – 2025 PRE-BOOK PROCESS

Step 1 - Review your current seasonal influenza data to determine your flu vaccine need for the entire season

Step 2 - Utilize the VFC Flu Vaccine Pre-Book Worksheet (IMM 1454) to prepare your request prior to accessing the online pre-book form.

Step 3 – Log-in to your MyVFCvaccines account and click on the “Pre-book Flu Vaccine for 2024-2025” button.

Step 4 – Allocate Seasonal Doses by Age Groups Served and Brand Preference

Step 5 – Submit your 2024-2025 VFC flu vaccine pre-book by Friday, February 2, 2024.
Flu Vaccine Formulation for the 2024-2025 Season
Transition to Trivalent Vaccine & Your VFC Pre-book

Background

• Global influenza surveillance has detected zero confirmed influenza B/Yamagata viruses since March 2020.

• Following the October 5, 2023, Vaccines and Related Biological Products Advisory Committee (VRBPAC) Meeting, FDA provided direction for manufacturers to plan for a transition to trivalent flu vaccine.

• As a result, flu vaccines available for the 2024-2025 season may reflect a mixture of trivalent and quadrivalent vaccines.
  • The quadrivalent vaccines contain 2 influenza A strains and 2 influenza B strains.
  • The trivalent vaccine will contain 2 influenza A strains and 1 influenza B strain.

VFC Pre-books

• The descriptions for flu vaccines in the pre-book do not reference the valency (i.e., trivalent or quadrivalent composition). When CDC confirms the valency after the pre-book, there may be updated NDCs.

• If changes occur, the VFC Program will notify providers of any updates to the NDCs, upon final confirmation of approved pre-books.

• Changes will not be made to the brands, presentations, or quantities.
Expanded Vaccine Recall of Certain Lots of Merck’s VAXNEUVANCE™

- In **July 2023**, Merck and the VFC Program had previously sent notices about a voluntary recall of certain lots of VAXNEUVANCE™ vaccine.

- Merck is expanding the voluntary recall for VAXNEUVANCE™ due to customer reports of breakage at the syringe flange and/or hub.

- This voluntary partial recall is specific to defects in the syringe and is not related to a quality or safety concern with the vaccine substance manufactured by Merck that is inside the syringe.

- Details about this recall are included in the notification packet that Merck is sending to all providers who received vaccine from one or more of the recalled lots, with specific instructions on returning remaining products.
  - Sedgwick is managing the recall process.

- VFC will be sending out general and targeted communications about the recall to providers.
VAXNEUVANCE™ Recall FAQs

• If already administered, are the recalled lots considered a valid dose?
  • Any administered doses of the recalled lots would still be considered valid. Merck’s recall is regarding the syringe breakage and not about the quality of the vaccine itself.

• How should providers account for the recalled vaccine?
  • Since the recalled lots should be returned to Merck via Sedgwick, VFC Providers will not be able to return the vaccines as they would other VFC vaccines. Instead, please submit a Wastage Form through your myVFCvaccines account to report these doses as non-usable but cannot be returned to the VFC Program.

• If you received one of the recalled lots, how can you receive more vaccine?
  • You can place a supplemental vaccine order on myVFCvaccines to request more VAXNEUVANCE® vaccine. If your last order was more than 30 days ago, please include your full vaccine inventory for your other available vaccines on your order form to help with vaccine accountability.
Vaccine Management
Josh Pocus, My Turn, Claudia Aguiluz, myCAvax, and Hannah Shows (Demo)
What’s New in My Turn? – Release 47 (1 of 2)

New updates for Patients launched on Tuesday, January 9, 2024!

Release Highlights

Patients will be able to view:

✓ The ‘Single dose’ and ‘Both doses’ options for the question ‘Which appointment would you like to schedule for the mpox vaccine?’ on the ‘Walk-in’ page
✓ An updated copy for the question ‘Which appointment would you like to schedule for the mpox vaccine?’
✓ An updated copy on mpox tags on clinic cards on the ‘Walk-in’ page
New updates for Clinic Managers and Vaccine Administrators
launched on **Tuesday, January 9, 2024**!

**Release Highlights**

Clinic Managers and Vaccine Administrators will be able to:

- ✓ CQE: Edit previously submitted records when the populated data is incorrect
- ✓ CQE: View all new records uploaded by other users from the same provider location but can only edit the records they have created
- ✓ CQE: View new dropdown options added to the 'Vaccine,' 'Vaccine Family,' 'Manufacturers,' and 'Package Information' fields on the CSV template
- ✓ My Turn Clinic: View new help text added to the 'Date of Birth,' ‘Ethnicity,’ ‘Specify Race / Nationality,’ 'Date Administered,' and ‘Parent or Guardian’s First Name’ fields
- ✓ My Turn Clinic: Update and resubmit the appointment with the new products if the product selected during the appointment is an old flu product and was created on or after July 1, 2023
Introducing California Immunization Registry (CAIR) Quick Entry

Since the My Turn Release 46 on Wednesday, December 20, 2023, CAIR Quick Entry allows users to submit, view, and edit vaccine administration data for most vaccines to Immunization Information Systems (IIS).
With the CAIR Quick Entry feature in My Turn, clinicians gain the ability to:

- **Report Vaccine Administration Data**: CAIR Quick Entry allows clinicians to report vaccine administration data to IIS. Note that a My Turn account is required to use CAIR Quick Entry. Clinicians are not required to manage vaccine appointments in My Turn.

- **Achieve Comprehensive Reporting**: CAIR Quick Entry can be used to report data for all vaccines accepted by CAIR, including flu, mpox, and COVID-19 vaccine.

- **Explore the Streamlined Process with My Turn**: If My Turn is clinicians’ preferred platform for managing appointment scheduling, vaccine administration data will continue to be reported to IIS using the usual process.
1. Using CAIR Quick Entry
Known Issues

Date Administered Discrepancy: Backend vs. Clinic Portal
✓ We fixed an issue where the Date Administered information on the backend did not match the date presented on the clinic portal.

Funding Source is Showing Up as ‘Unknown’ on the CAIR2 Side
✓ We have addressed an issue where the vaccines were documented in My Turn with a funding source as ‘State General Funding.’ However, CAIR2 read the funding source as ‘Unknown.’

Workaround / Next Steps
✓ Fixed: Tuesday, January 9, 2024
✓ Fixed: Tuesday, January 9, 2024
✓ My Turn accurately transmits ‘State General Funding.’ However, the term ‘Unknown’ in the CAIR2 portal was not sourced from My Turn and instead, linked to a particular lot number in the site’s existing inventory, and the funding source information was not preserved when the lot inventory reached zero.
Vaccines for Adults (VFA) / LHD 317 Program Timeline and Next Steps

October 2023
- Final myCAvax Release until February
- VFA / LHD 317 Ordering in the VFC system
- Development for the VFA / LHD 317 program begins
- Data migration activities begin

November 2023
- LHD 317 Ordering in the VFC system
- VFA off-cycle for Orders
- Development for the VFA / LHD 317 program continues
- First round of User Acceptance Testing (UAT) for the VFA / LHD 317 program
- Data migration activities continue

December 2023
- Recertification opens for the VFA / LHD 317 program in the VFC system
- LHD 317 Ordering in the VFC system
- VFA off-cycle for Orders
- Development for the VFA / LHD 317 program continues
- Second round of UAT for the VFA / LHD 317 program
- Data migration activities continue

January 2024
- Recertification closes for the VFA / LHD 317 program in the VFC system
- VFA / LHD 317 Ordering in the VFC system – closes by the end of January
- Training for CDPH
- Development for the VFA / LHD 317 program continues
- Third round of UAT for the VFA / LHD 317 program
- Data migration activities continue

February 2024+
- Development for the VFA / LHD 317 program completes
- Final round of UAT for VFA / LHD 317
- Data migration activities complete
- Recertification for the VFA / LHD 317 program in the myCAvax system
- Training for providers
- VFC system shut-down for the VFA / LHD 317 program
- LHD 317 Ordering in the myCAvax system
- VFA Ordering in April in the myCAvax system
VFA Upcoming Actions for Providers

Vaccine Orders
- Last day to submit vaccine orders and transfers (if applicable) in MyVFCvaccines.

NOTE: Ordering will be closed until next VFA quarterly cycle (April 2024).

Account Management
- Complete recertification part 1 in MyVFCvaccines.
- Review and update your site’s VFA contact.

Vaccine Orders
- Submit order corrections if needed.

Training
- Identified VFA key practice staff should register and attend the training on February 22 and 29, 2024.

By February 9, 2024
Ensure all VFA program transactions have been recorded in MyVFCvaccines by EOD.

Last day in MyVFCvaccines for:
- Recording shipment incidents, temperature excursions, waste and transfers.

February 10 - 19, 2024
Transition Week
- VFA program data will be migrated to myCAvax.

Go Live
First day in myCAvax for:
- Completing recertification part 2 by verifying clinic information and updating key practice staff managing the adult population
- Completing all required training (lesson details forthcoming)
- Signing the VFA agreement and addendum via Docusign

February 20, 2024

CDPH Training
- Register and attend the VFA 101 Training for Providers at 11:00 AM PT.
- NOTE: Your identified VFA key practice staff should register for the above training and will receive email in early February regarding training reminders and next steps.

February 22, 2024
CDPH Training
- Register and attend the VFA 102 Training for Providers training at 11:00 AM PT.
- NOTE: Your identified VFA key practice staff should register for the above training and will receive email in early February regarding training reminders and next steps.

February 29, 2024

Ensure all VFA program transactions have been recorded in MyVFCvaccines by EOD.

Last day in MyVFCvaccines:
- Recording shipment incidents, temperature excursions, waste and transfers.

January 25, 2024

January 31, 2024

February 10, 2024

February 20, 2024

February 29, 2024

NOTE: While we transition the VFA program into myCAvax, continue to manage VFC vaccines in MyVFCvaccines.
With the VFA / LHD 317 programs being released in myCAvax on **Tuesday, February 20, 2024**, CDPH will begin system training for LHDs and providers.

Identified VFA key practice staff should attend 2 trainings:

- **VFA 101 Training for Providers** on **Thursday, February 22, 2024**, at 11:00 am PST
- **VFA 102 Training for Providers** on **Thursday, February 29, 2024**, at 11:00 am PST

Register on Zoom for both trainings.
With the VFA / LHD 317 program being released in myCAvax on **Tuesday, February 20, 2024**, all the VFA / LHD 317 providers must complete the recertification process.

During the VFC recertification process, all the VFA and LHDs providers must:

- Enter / update clinic information in MyVFCvaccines by **Wednesday, January 31, 2024**; this information will be migrated and pre-populated in the myCAvax recertification form.
- Review and update their site's VFA contact on MyVFCvaccines. This will be the only key practice staff information migrated to myCAvax. The VFA contact will be designated as the Primary Vaccine Coordinator in myCAvax.

After VFA / LHD 317 release in myCAvax on **Tuesday, February 20, 2024**:

- Complete the information verification process in myCAvax in **February 2024**
- Update the key practice staff managing the adult population on myCAvax
- Complete all required EZIZ training (Lesson details forthcoming)

The Provider of Record must review, acknowledge, and sign the VFA / LHD 317 Agreement and Addendum on myCAvax to complete the recertification process.
Allocations of BAP COVID-19 vaccine products are refreshed on a biweekly cadence. CDPH receives allocations mid-week and distributes inventory to the LHDs within a few business days.

The most recent CDC allocation refresh was received Wednesday, January 17, 2024. Doses were added to LHD allocations the same day.
Reminder: New Refrigerated Pfizer COVID-19 Vaccine for 12 Years+

The previous Pfizer 12y+ vaccine allocations have been replaced with Pfizer's new refrigerated 12y+ vaccine (NDC 00069-2377-10), a new presentation in a carton of 10 manufacturer-filled syringes (MFS).

Providers who have the original Pfizer 12y+ vaccine on hand can and should continue to use this product until it is consumed, expired, or has been stored at 2–8 °C for longer than the allowable 10 weeks.

**Important:** There are no temperature monitors being shipped with this product. Shipments maintain temperatures for 84 hours. **Please check the shipment’s date (on the shipment label outside)** to ensure it is received within this timeframe.
Beginning this week, McKesson will temporarily be using one of the two warm temperature monitors for vaccine shipment. Coolers may contain the familiar 3M monitor or the new monitor, SpotSee (WarmMark).

This temporary change in temperature monitors is expected to be in place until **Thursday, February 1, 2024**, when a new and improved temperature monitor will be used for refrigerated shipments. See [Supplemental Resource on Temporary Loggers](#) provided by McKesson for additional support.

Both the 3M and SpotSee monitors are one-time use only and should be disposed of once the vaccine has been properly stored.

Please follow the same process for checking any temperature excursions and follow the directions on the information card specific to the monitor received.
## January Holiday Ordering & Distribution Cadence Calendar

**California BAP COVID-19 Vaccination Program** (Providers/LHDs)

<table>
<thead>
<tr>
<th>Monday</th>
<th>Tuesday</th>
<th>Wednesday</th>
<th>Thursday</th>
<th>Friday</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 01</td>
<td>02</td>
<td>03</td>
<td>04</td>
<td>05</td>
</tr>
<tr>
<td><strong>Holiday Hold – No Vaccine Deliveries</strong></td>
<td><strong>Provider Order (submit by 3PM)</strong></td>
<td><strong>LHD Approval by 12PM</strong></td>
<td><strong>CDPH Transmits to CDC</strong></td>
<td><strong>Estimated Delivery – McKesson (Moderna/Novavax) &amp; Pfizer</strong></td>
</tr>
<tr>
<td>08</td>
<td>09</td>
<td>10</td>
<td>11</td>
<td>12</td>
</tr>
<tr>
<td><strong>Provider Order (submit by 5PM)</strong></td>
<td><strong>LHD Approval by 12PM</strong></td>
<td><strong>CDPH Transmits to CDC</strong></td>
<td><strong>Estimated Delivery – McKesson (Moderna/Novavax) &amp; Pfizer</strong></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>16</td>
<td>17</td>
<td>18</td>
<td>19</td>
</tr>
<tr>
<td><strong>Holiday Hold – No Vaccine Deliveries</strong></td>
<td><strong>Estimated Delivery – McKesson (Moderna/Novavax) &amp; Pfizer</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Delivery windows are dependent on provider’s days/hours of operation. Shipment will be sent the following week of order approval and processing. (**Adjusted Delivery date due to Holiday**)
- Watch for emails regarding order confirmations, advance shipment notices of vaccine, and temperature monitoring alerts.
## January Holiday Ordering & Distribution Cadence Calendar

**California SGF Flu Vaccination Program (Providers/LHDs)**

<table>
<thead>
<tr>
<th>Monday</th>
<th>Tuesday</th>
<th>Wednesday</th>
<th>Thursday</th>
<th>Friday</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 01</td>
<td>02</td>
<td>03</td>
<td>04</td>
<td>05</td>
</tr>
<tr>
<td></td>
<td>LHD Approval by 12PM</td>
<td>CDPH Transmits to CDC</td>
<td>LHD Approval by 12PM</td>
<td>CDPH Transmits to CDC</td>
</tr>
<tr>
<td>Holiday Hold – No Vaccine Deliveries</td>
<td></td>
<td>Flu Vaccine Delivery – McKesson Direct Ship</td>
<td>Provider Order (submit by 5PM)</td>
<td>Provider Order (submit by 5PM)</td>
</tr>
<tr>
<td>08</td>
<td>09</td>
<td>10</td>
<td>11</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>LHD Approval by 12PM</td>
<td>CDPH Transmits to CDC</td>
<td>LHD Approval by 12PM</td>
<td>CDPH Transmits to CDC</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Flu Vaccine Delivery – McKesson Direct Ship</td>
<td>Provider Order (submit by 5PM)</td>
<td>Provider Order (submit by 5PM)</td>
</tr>
<tr>
<td></td>
<td>15</td>
<td>16</td>
<td>17</td>
<td>18</td>
</tr>
<tr>
<td>Holiday Hold – No Vaccine Deliveries</td>
<td></td>
<td>LHD Approval by 12PM</td>
<td>CDPH Transmits to CDC</td>
<td>LHD Approval by 12PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Flu Vaccine Delivery – McKesson Direct Ship</td>
<td>Provider Order (submit by 5PM)</td>
<td>Provider Order (submit by 5PM)</td>
</tr>
</tbody>
</table>

⚠️: Delivery windows are dependent on provider’s days/hours of operation. Shipments will be sent the following week of order approval and processing. [** Adjusted Delivery date due to Holiday**]

Watch for emails regarding order confirmations, advance shipment notices of vaccine, and temperature monitoring alerts.
# Slide Icon Key

<table>
<thead>
<tr>
<th>Icon</th>
<th>Meaning</th>
</tr>
</thead>
<tbody>
<tr>
<td>🌟</td>
<td>This is to label slides that are referencing upcoming or existing functionality and how to use it in the system.</td>
</tr>
<tr>
<td>🕒</td>
<td>This is to label slides that include important system reminders.</td>
</tr>
<tr>
<td>💡</td>
<td>This is to label slides that include tips and best practices to improve your system experience.</td>
</tr>
</tbody>
</table>
Known Issues

Transfer and Order Related List Views Tied Together
✓ We will be correcting a visibility issue in which Sending Transfers are only visible on a Vaccine Order’s related list views when looking at an Account or Program Location. While Receiving Transfers have their own unique related list view, Sending Transfers should also have their own unique related list view.

Some Sending Transfers Missing from Program Related List Views
✓ We will be correcting an issue in which some Sending Transfers are not showing in their respective Program Location's related list views but are still visible from their Account's related list views – for now, the Account should be taken as the source of truth if you notice a mismatch.

Workaround / Next Steps
✓ Estimated Fix: February 2024
Resources and Q&A
Leslie Amani and CDPH SMEs
COVID-19 Vaccine and Therapeutics FAQs

Answers to providers’ COVID-19 vaccine and therapeutics questions!

Updated Thursday, January 11, 2024

**Q: Where can I find information about COVID-19 vaccination and pregnancy?**

A: COVID-19 vaccination is recommended for people who are pregnant, breastfeeding, trying to get pregnant now, or might become pregnant in the future. For patient resources, please refer to [CDPH Pregnancy and Immunizations Toolkit](#).

**Q: Is there a refrigerated presentation of COVID-19 vaccine?**

A: Yes. There is a new refrigerated Pfizer 12y+ COVID-19 vaccine. This new presentation comes as single-dose pre-filled syringes and must be stored between 2°C - 8°C (36°F and 46°F). For more information and resources, please refer to this [CDPH communication](#), the updated [COVID-19 Vaccine Adolescent/Adult (12Y+) fact sheet](#), and the updated [COVID-19 Vaccine Product Guide](#).
Special Note for Providers

You played a critical role in helping to end the COVID-19 pandemic.

For patients, you are one of the most trusted sources of information when it comes to vaccines. Patients may have questions and concerns about COVID-19 vaccines. You can help them understand the importance of vaccination, provide your strong recommendation, and build confidence in vaccines.

Strong vaccine confidence leads to more people getting vaccinated, which leads to fewer COVID-19 illnesses, hospitalizations, and deaths.

Thank you for the efforts you and your practice staff are making to keep California healthy.
Vaccine Support

Provider Call Center
Dedicated to medical providers and Local Health Departments in California, specifically addressing questions about State program requirements, enrollment, and vaccine distribution.

- For myCAvax Help Desk inquiries: myCAvax.hd@cdph.ca.gov
- For My Turn Clinic Help Desk inquiries: MyTurn.Clinic.HD@cdph.ca.gov
- For all other inquiries: providercallcenter@cdph.ca.gov
- Phone: (833) 502-1245, Monday through Friday from 8AM–5PM

myCAvax

- Virtual Assistant resolves many questions but will direct you to the Provider Call Center queue for live assistance!
- Knowledge Center houses key job aids and videos that are updated every release. Once logged in, you can access job aids from the myCAvax homepage (or at various places throughout the system) using the links as shown below.

Need help? View our job aids in the Knowledge Center, or contact us.
## COVID-19 Therapeutics Resources

<table>
<thead>
<tr>
<th>Type of Support</th>
<th>Description</th>
<th>Updated 11.27.23</th>
</tr>
</thead>
</table>
| **Clinical Guidance**   | For general Therapeutics questions, please email: [COVIDRxProviders@cdph.ca.gov](mailto:COVIDRxProviders@cdph.ca.gov)  
                           COVID-19 Treatment Warline for SNF and LTCF staff: 1.866.268.4322 M-F 8am-5pm |                 |
| **General Information**  | CDPH COVID-19 Treatments Webpage (provides general information for healthcare providers, allocations,  
                             distribution and ordering, drug facts sheets, and additional resources)  
                             CDPH COVID-19 Treatments Job Aid (questions and answers for the public on COVID-19 therapeutics)  
                             COVID-19 Therapeutics Best Practices Checklist (testing, prescribing, dispensing, and more)  
                             Frequently Asked Questions document for clinics, providers, and pharmacists |                 |
| **Locating Resources**  | Finding Providers and Test-to-Treat Sites  
                             - [COVID-19 Therapeutics Locator](https://arcgis.com) (arcgis.com)  
                             - Test-to-Treat (hhs.gov) |                 |
| **LHJ Therapeutics SharePoint** | Primary source for recorded webinars, slides, datasets and HPOP reporting information. (For access, email [JEOCuser54@cdph.ca.gov](mailto:JEOCuser54@cdph.ca.gov))  
                             - Therapeutic Weekly Email Update files (SharePoint)  
                             - CDPH Therapeutics HPoP Account Verification & Reporting information |                 |
| **Questions**            | For general CDPH Therapeutics questions, please email [COVIDRxProviders@cdph.ca.gov](mailto:COVIDRxProviders@cdph.ca.gov)  
                           For ordering, program inquiries, signing up new HPOP Accounts: please e-mail [CDPHTherapeutics@cdph.ca.gov](mailto:CDPHTherapeutics@cdph.ca.gov) |                 |
Questions

During today's webinar, please use the Q&A panel to ask your questions so CDPH subject matter experts can respond directly.

Resource links will be dropped into, “Chat”
Upcoming CDPH Webinar Opportunities

**CDPH Immunization Updates for Providers**

*Next session: Friday, January 26, 2024*

*9AM – 10:30AM*